Skip to content
DataLookout
Menu

EXPANDNCT06956014

Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 40 → 43 locations
    • Trial sites expanded: 32 → 40 locations
  2. Minor Study sites: 32 to 40
  3. Minor Trial sites expanded: 22 → 32 locations
  4. Minor Trial sites expanded: 1 → 22 locations
  5. Minor Study sites: 1 to 22
  6. Notable Recruitment opened
    • Eligibility criteria expanded, about 6 words
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 2026 to Sep 22, 2026
  7. Notable Primary and study completion pushed from Nov 2027 to Sep 2028
    • Eligibility criteria shortened, about 80 words
    • Study title shortened, about 1 word
    v4
  8. Notable Start date: Mar 2026 to Sep 2026v3 Show 4 more changesShow less
    • Eligibility criteria expanded, about 16 words
    • Enrollment target: 700 to 810
    • Primary and study completion dates: Sep 2027 to Nov 2027
    • Study title expanded, about 1 word
  9. Notable Start date: Nov 2025 to Mar 2026
    • Primary and study completion dates: May 2027 to Sep 2027
    v2
  10. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Efficacy based on pain reduction
Timeframe: From Baseline to Treatment Week 12

Arms and interventions

VER-01 Dose 1Experimental
VER-01 Dose 2Experimental
PlaceboPlacebo comparator

Drugs: VER-01

Other: Placebo

Sites

43 sites in 1 country